HC Wainwright Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price

PDS Biotechnology (NASDAQ:PDSB) had its target price cut by analysts at HC Wainwright from $21.00 to $13.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock.

PDS Biotechnology Trading Down 0.4 %

PDS Biotechnology stock traded down $0.01 during mid-day trading on Thursday, hitting $1.24. The stock had a trading volume of 188,746 shares, compared to its average volume of 645,391. The stock has a 50-day simple moving average of $1.41 and a two-hundred day simple moving average of $2.18. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $47.17 million, a PE ratio of -1.06 and a beta of 1.68. PDS Biotechnology has a 12 month low of $1.13 and a 12 month high of $4.56.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Thursday, March 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.10. As a group, sell-side analysts forecast that PDS Biotechnology will post -1.2 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PDSB. Geode Capital Management LLC boosted its holdings in PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after buying an additional 37,142 shares during the last quarter. Blair William & Co. IL boosted its stake in PDS Biotechnology by 29.4% during the 4th quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock worth $257,000 after acquiring an additional 35,757 shares during the last quarter. Renaissance Technologies LLC boosted its stake in PDS Biotechnology by 331.0% during the 4th quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock worth $163,000 after acquiring an additional 76,800 shares during the last quarter. XTX Topco Ltd increased its stake in PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after purchasing an additional 47,528 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in PDS Biotechnology by 273.5% in the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock valued at $107,000 after purchasing an additional 48,132 shares in the last quarter. 26.84% of the stock is currently owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.